Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Telik was incorporated in October 1988 as Terrapin Diagnostics Inc, which changed its name in June 1989 to Terrapin Technologies Inc and again in May 1998 to Telik Inc. Telik is a biopharmaceutical company working to discover, develop and commercialise small-molecule drugs to treat cancer and other serious diseases, such as Type II diabetes and inflammation, for which there is significant demand for new therapies.